stockrowargenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.
- Revenue
- +52.1%
- EPS
- +43.9%
- Free cash flow
- +537.5%
Quarter to September 2026, against a year earlier
Follow ARGX
Alert me
argenex SE (ARGX) Operating cash flow
argenex SE's operating cash flow for fiscal 2025 was $685.2M, compared with −$82.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.6B. Over the past ten years it has ranged from −$862.8M (fiscal 2022) to $685.2M (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 3 consecutive fiscal years. argenex SE ranks 5th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $685.2M | — |
| FY2024 | −$82.7M | — |
| FY2023 | −$420.3M | — |
| FY2022 | −$862.8M | — |
| FY2021 | −$606.8M | — |
| FY2020 | −$398.5M | — |
| FY2019 | $150.7M | — |
| FY2018 | −$63.6M | — |
| FY2017 | −$41.3M | — |
| FY2016 | $11.7M | — |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. compare | $4.8B |
| RPRX Royalty Pharma PLC compare | $3.0B |
| ARGX argenex SE | $1.6B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.6B |
| GMAB Genmab A/S Sponsored ADR compare | $891.0M |
| INCY Incyte Corporation compare | $745.0M |
| ROIV Roivant Sciences Ltd. compare | −$816.5M |
| MRNA Moderna, Inc. compare | −$1.1B |
| RVMD Revolution Medicines, Inc. compare | −$1.4B |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on ARGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement